Neuphoria Therapeutics (NEUP) AI Stock Analysis

• Market Cap: $23.83M
• Dividend Yield: N/A
• Average Volume (3M): 89.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): N/A
• Shares Outstanding: 5,390,895
• 10 Day Avg. Volume: 91,705
• 30 Day Avg. Volume: 89,214
• PEG Ratio: -0.16
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.48
• P/FCF Ratio: 0.15
• Enterprise Value/Market Cap: -0.59
• Enterprise Value/Revenue: -1.70
• Enterprise Value/Gross Profit: -1.74
• Enterprise Value/Ebitda: 0.02
• 1Y Price Target: $7.00
• Price Target Upside: 60.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $4.00 ▼(-8.05% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is held back primarily by very weak profitability and a negative P/E, alongside a longer-term technical downtrend. Offsetting these are a low-leverage balance sheet and a notable improvement to strongly positive TTM operating and free cash flow, though its durability is uncertain given the large reported losses.

Positive Factors

Low leverage / strong balance sheet

No reported debt and positive equity provide meaningful financial flexibility for a capital-intensive pharmaceutical developer. Reduced solvency risk supports continued R&D spending, partnership negotiations, or pursuing strategic transactions without immediate refinancing pressure.

Positive trailing cash generation

A materially positive TTM operating and free cash flow position improves near-term liquidity and optionality for funding programs or M&A. If sustained, this cash generation can fund clinical activities or bridge to strategic deals, reducing reliance on external capital.

Very high gross margins where revenue exists

Extremely high gross margins imply favorable unit economics for existing products or services. If revenue growth resumes, these margins offer strong operating leverage potential, enabling faster improvement in profitability as fixed R&D and overhead are spread over higher sales.

Negative Factors

Deep and persistent net losses

Very large net losses relative to revenue indicate structural burn from R&D/opex that far exceeds current sales. Persistent negative returns erode shareholder value and require ongoing funding or transformational transactions to restore sustainable profitability over the medium term.

Declining revenue base

A small and shrinking revenue base constrains the company's ability to leverage high gross margins and achieve scale. Continued top-line decline limits internal funding for development and increases reliance on external capital or deals, raising medium-term execution risk.

Leadership transition and limited interim CEO role

Shifting the CEO from full-time to a part-time consulting interim role during a planned strategic transaction can slow execution and concentrate decision-making around a deal. This signals dependence on a transaction and creates near-term leadership continuity and governance risks for long-term strategy delivery.

Neuphoria Therapeutics Business Overview & Revenue Model

Company Description

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

How the Company Makes Money

Neuphoria Therapeutics Financial Statement Overview

Summary

Mixed fundamentals: income statement is very weak (declining modest revenue and extremely large losses), but the balance sheet shows low leverage/no debt and positive equity, and cash flow has turned strongly positive in TTM. Sustainability of cash generation is a key risk given the mismatch between large losses and positive operating/free cash flow.

Income Statement

Results remain loss-making and volatile. In TTM (Trailing-Twelve-Months), revenue is modest (~$8.2M) and declining (about -11.5%), while profitability is deeply negative with a very large operating loss and a net loss of roughly $373M (net margin about -45x revenue), indicating heavy R&D/operating spend relative to the current revenue base. The main positive is strong gross profitability where revenue exists (TTM gross margin ~98%), but the cost structure overwhelms it and limits near-term earnings visibility.

Balance Sheet

Leverage appears low on the periods shown, with TTM showing no debt and positive equity (~$29.7M), and prior annual periods showing very low debt relative to equity (debt-to-equity in the low single-digit percentages or below). This supports financial flexibility and reduces solvency risk. The key weakness is weak returns: return on equity is negative across periods, reflecting continued losses and limited balance-sheet productivity despite low leverage.

Cash Flow

Cash flow has improved meaningfully versus earlier years: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are strongly positive (~$74.8M), following multiple years of negative operating and free cash flow (e.g., 2021–2024). However, free cash flow growth in TTM is slightly negative (~-4%), and the sharp mismatch between very large reported losses and positive operating cash flow suggests results may be influenced by working-capital swings or non-cash items, which can be less repeatable.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	8.21M	23.95M	0.00	0.00	―	0.00
Gross Profit	8.03M	22.94M	-992.56K	-671.42K	0.00	-1.69M
EBITDA	-847.52M	-268.02K	-22.33M	-21.54M	-28.03M	-6.63M
Net Income	-373.34M	-565.77K	-23.19M	-21.65M	-22.94M	-8.65M
Balance Sheet
Total Assets	36.60M	28.59B	27.65M	19.39M	44.93M	40.77M
Cash, Cash Equivalents and Short-Term Investments	22.17M	14.21B	12.61M	8.06M	23.09M	21.41M
Total Debt	50.13K	116.31M	272.74K	257.55K	477.15K	652.04K
Total Liabilities	6.90M	9.59B	10.16M	4.74M	5.78M	5.01M
Stockholders Equity	29.70M	19.00B	17.49M	14.65M	39.15M	35.76M
Cash Flow
Free Cash Flow	74.79M	77.23M	-14.68M	-9.85M	-14.97M	-5.67M
Operating Cash Flow	74.79M	77.23M	-14.68M	-9.85M	-14.97M	-5.66M
Investing Cash Flow	0.00	0.00	0.00	0.00	427.68K	-60.26K
Financing Cash Flow	1.55B	1.53B	15.11M	2.60M	18.57M	23.71M

Neuphoria Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RNTX	53 Neutral	$29.18M	-0.42	-83.28%	―	―	15.35%
TXMD	52 Neutral	$26.85M	89.27	0.27%	―	75.19%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NEUP	48 Neutral	$23.83M	-0.18	-59.91%	―	―	―
SINT	40 Underperform	$11.56M	-0.46	-204.04%	―	-60.89%	94.49%
BIVI	38 Underperform	$9.50M	-0.25	-94.79%	―	―	84.44%

Neuphoria Therapeutics Corporate Events

Neuphoria Therapeutics Announces CEO Transition and Consulting Role

Neuphoria Therapeutics Inc. announced that Spyridon “Spyros” Papapetropoulos, M.D., who was appointed president and CEO under an employment agreement effective January 5, 2023, will step down as full-time president and CEO effective December 31, 2025, while remaining on the company’s board of directors. Under his employment agreement, he will receive severance equal to his annual base salary, target bonus and medical insurance premiums, paid partly in 2025 and the remainder in installments through 2026, and his participation in most employee benefit programs will end immediately, though his existing stock options will continue to vest and be exercisable under the company’s equity plan. Concurrently, Papapetropoulos has entered into a consulting agreement effective January 1, 2026, under which he will serve as interim CEO for up to twelve months at an hourly consulting rate, limited to roughly 40 hours per month, to support a planned strategic transaction and oversee leadership transition, with the arrangement set to terminate earlier if the company completes a strategic merger, change of control or similar deal.

The most recent analyst rating on (NEUP) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page.

Neuphoria Therapeutics Shareholders Align on Key Proposals

On December 12, 2025, Neuphoria Therapeutics held its Annual Meeting of Shareholders, during which voting took place on four key proposals related to corporate governance and strategy. The proposals included the election of two Class I directors for a three-year term, the ratification of Wolf & Company P.C. as the company’s auditors for the fiscal year ending June 30, 2026, a non-binding vote on executive compensation, and a decision on the frequency of future advisory votes on executive pay. The results demonstrated shareholder support across all proposals, suggesting an alignment between company management and its shareholders on governance and strategic priorities.

The most recent analyst rating on (NEUP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page.